Eupraxia Pharmaceuticals, a clinical-stage biotech company specializing in targeted drug delivery technology, announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company focuses on its proprietary Diffusphere™ technology, which aims to improve drug safety and efficacy by delivering medication locally and in a controlled manner. Eupraxia is currently advancing clinical trials for treatments targeting eosinophilic esophagitis and knee osteoarthritis. This presentation offers investors insight into Eupraxia's progress and future pipeline developments.
ZYT (ZHUOYU Technology) officially inaugurated its European headquarters in Braunschweig, Germany, marking a key step in its 'In Europe, for Europe' strategy. The company announced collaborations with Volkswagen Group to pilot intelligent driving on ...
The global battery energy storage system (BESS) market is projected to grow from $89.89 billion in 2026 to $198.88 billion by 2031, at a CAGR of 17.21%. Growth is fueled by declining lithium-ion battery costs, government policies like the U.S. Inflat...
Olenox Industries Inc. shares surged 61.79% in after-hours trading following the closing of its $30 million acquisition of CS Digital Ventures, a company specializing in energy-intensive data centers and digital infrastructure. The deal combines Olen...
VINCI has finalized its acquisition of Fletcher Construction, a major New Zealand company with annual revenue of about €630 million and 2,300 employees. This move strengthens VINCI Construction's position in New Zealand's growing infrastructure marke...
VINCI has finalized its acquisition of Fletcher Construction, a New Zealand company with annual revenue of about 630 million euros and 2,300 employees. This move strengthens VINCI Construction's network in New Zealand, complementing previous acquisit...
